|
|
|
|
||
Tweet, a few days ago, fyiWILLOW study imminent in 1Q20 INSM is calling it a "lottery ticket" study, company hasn't seen another DPP1 show the impact they hope to demonstrate $INSM Powered to show a 40% diff in rate of pulmonary exacerbations INSM is not looking for statistical significance, only "directional evidence" (a 20% reduction), will cancel program if not Even if 1007 does not hit, they are confident in the value of Arikayce |
return to message board, top of board |